Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Animals
2.3. Veterinary Evaluations
2.4. Supplement
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Polzin, D.J. Chronic kidney disease in small animals. Vet. Clin. N. Am. Small Anim. Pract. 2011, 41, 15–30. [Google Scholar] [CrossRef] [PubMed]
- Polzin, D.J. Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats. J. Vet. Emerg. Crit. Care 2013, 23, 205–215. [Google Scholar] [CrossRef] [PubMed]
- Bartges, J.; Polzin, D.J. (Eds.) Nephrology and Urology of Small Animals; Wiley: Hoboken, NJ, USA, 2011. [Google Scholar] [CrossRef]
- Bartges, J.W. Chronic kidney disease in dogs and cats. Vet. Clin. N. Am. Small Anim. Pract. 2012, 42, 669–692. [Google Scholar] [CrossRef] [PubMed]
- Lippi, I.; Perondi, F.; Gori, E.; Pierini, A.; Bernicchi, L.; Marchetti, V. Serum Bicarbonate Deficiency in Dogs with Acute and Chronic Kidney Disease. Vet. Sci. 2023, 10, 363. [Google Scholar] [CrossRef]
- Finco, D.R.; Brown, S.A.; Crowell, W.A.; Duncan, R.J.; Barsanti, J.A.; Bennett, S.E. Effects of dietary phosphorus and protein in dogs with chronic renal failure. Am. J. Veter Res. 1992, 53, 2264–2271. [Google Scholar] [CrossRef]
- King, J.N.; Tasker, S.; Gunn-Moore, D.A.; Strehlau, G. Prognostic factors in cats with chronic kidney disease. J. Vet. Intern. Med. 2007, 21, 906–916. [Google Scholar] [CrossRef]
- Boyd, L.; Langston, C.; Thompson, K.; Zivin, K.; Imanishi, M. Survival in cats with naturally occurring chronic kidney disease. J. Vet. Intern. Med. 2008, 22, 1111–1117. [Google Scholar] [CrossRef]
- Foster, J.D. Update on mineral and bone disorders in chronic kidney disease. Vet. Clin. N. Am. 2016, 46, 1131–1149. [Google Scholar] [CrossRef]
- Lippi, I.; Guidi, G.; Marchetti, V.; Tognetti, R.; Meucci, V. Prognostic role of the product of serum calcium and phosphorus concentrations in dogs with chronic kidney disease: 31 cases (2008–2010). J. Am. Vet. Med. Assoc. 2014, 245, 1135–1140. [Google Scholar] [CrossRef]
- Parker, V.J. Nutritional Management for Dogs and Cats with Chronic Kidney Disease. Vet. Clin. Small Anim. 2021, 51, 685–710. [Google Scholar] [CrossRef]
- Elliot, J.; Brown, S.; Cowgill, L. Symposium on Phosphatemia Management in the Treatment of Chronic Kidney Disease; Vetoquinol: Louisville, KY, USA, 2006. [Google Scholar]
- International Renal Interest Society. Treatment Recommendations for CKD in Dogs. Available online: https://www.iris-kidney.com/s/IRIS-DOG-Treatment_Recommendations_2023.pdf (accessed on 5 May 2025).
- Parker, V.J.; Freeman, L.M. Association between body condition and survival in dogs with acquired chronic kidney disease. J. Vet. Intern. Med. 2011, 25, 1306–1311. [Google Scholar] [CrossRef]
- Pedrinelli, V.; Lima, D.M.; Duarte, C.N.; Teixeira, F.A.; Porsani, M.; Zarif, C.; Amaral, A.R.; Vendramini, T.H.A.; Kogika, M.M.; Brunetto, M.A.; et al. Nutritional and laboratory parameters affect the survival of dogs with chronic kidney disease. PLoS ONE 2020, 15, e0234712. [Google Scholar] [CrossRef]
- Martello, E.; Perondi, F.; Bruni, N.; Bisanzio, D.; Meineri, G.; Lippi, I. Chronic Kidney Disease and Dietary Supplementation: Effects on Inflammation and Oxidative Stress. Vet. Sci. 2021, 8, 277. [Google Scholar] [CrossRef]
- Behrend, E.N.; Kooistra, H.S.; Nelson, R.; Reusch, C.E.; Scott-Moncrieff, J.C. Diagnosis of Spontaneous Canine Hyperadrenocorticism: 2012 ACVIMConsensus Statement (Small Animal). J. Vet. Intern. Med. 2013, 27, 1292–1304. [Google Scholar] [CrossRef] [PubMed]
- Biasibetti, E.; Martello, E.; Bigliati, M.; Biasato, I.; Cocca, T.; Bruni, N.; Capucchio, M.T. A long term feed supplementation based on phosphate binders in Feline Chronic Kidney Disease. Vet. Res. Commun. 2018, 42, 161–167. [Google Scholar] [CrossRef] [PubMed]
- Rossi, G.; Bertazzolo, W.; Binnella, M.; Scarpa, P.; Paltrinieri, S. Measurement of proteinuria in dogs: Analytic and diagnostic differences using 2 laboratory methods. Vet. Clin. Pathol. 2016, 45, 450–458. [Google Scholar] [CrossRef] [PubMed]
- FEDIAF. Nutritional Guidelines 2014. Available online: https://www.fediaf.org/ (accessed on 5 May 2025).
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2024. [Google Scholar]
- Martello, E.; Perondi, F.; Capucchio, M.T.; Biasato, I.; Biasibetti, E.; Cocca, T.; Bruni, N.; Lippi, I. Efficacy of a new dietary supplement in dogs with advanced chronic kidney disease. PeerJ 2020, 8, e9663. [Google Scholar] [CrossRef]
- Cortadellas, O.; Fernández del Palacio, M.J.; Talavera, J.; Bayón, A. Calcium and phosphorus homeostasis in dogs with spontaneous chronic kidney disease at different stages of severity. J. Vet. Intern. Med. 2010, 24, 73–79. [Google Scholar] [CrossRef]
- Geddes, R.F.; Finch, N.C.; Syme, H.M.; Elliott, J. The role of phosphorus in the pathophysiology of chronic kidney disease. J. Vet. Emerg. Crit. Care 2013, 23, 122–133. [Google Scholar] [CrossRef]
- Jacob, F.; Polzin, D.J.; Osborne, C.A.; Neaton, J.D.; Kirk, C.A.; Allen, T.A.; Swanson, L.L. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J. Am. Vet. Med. Assoc. 2005, 226, 393–400. [Google Scholar] [CrossRef]
- Zatelli, A.; D’Ippolito, P.; Roura, X.; Zini, E. Short-term effects of dietary supplementation with amino acids in dogs with proteinuric chronic kidney disease. Can. Vet. J. Rev. Vet. Can. 2017, 58, 1287–1293. [Google Scholar]
- Miyakawa, P.H.; Ogawa, M.; Sakatani, A.; Akabane, R.; Miyagawa, Y.; Takemura, N. Evaluation of the progression of non-azotemic proteinuric chronic kidney disease in dogs. Res. Vet. Sci. 2021, 138, 11–18. [Google Scholar] [CrossRef] [PubMed]
- Finco, D.R. Association of systemic hypertension with renal injury in dogs with induced renal failure. J. Vet. Intern. Med. 2004, 18, 289–294. [Google Scholar] [CrossRef] [PubMed]
- Acierno, M.; Brown, S.; Coleman, A.E.; Jepson, R.E.; Papicj, M.; Stepien, S.; Syme, H.M. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J. Vet. Intern. Med. 2018, 32, 1803–1822. [Google Scholar] [CrossRef] [PubMed]
- Jacob, F.; Polzin, D.J.; Osborne, C.A.; Neaton, J.D.; Lekcharoensuk, C.; Allen, T.A.; Kirk, C.A.; Swanson, L.L. Association between initial systolic blood pressure and risk of developing a uremic crisis or of dying in dogs with chronic renal failure. J. Am. Vet. Med. Assoc. 2003, 222, 322–329. [Google Scholar] [CrossRef]
- Susalit, E.; Agus, N.; Effendi, I.; Tjandrawinata, R.R.; Nofiarny, D.; Perrinjaquet-Moccetti, T.; Verbruggen, M. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: Comparison with Captopril. Phytomed. Int. J. Phytother. Phytopharm. 2011, 18, 251–258. [Google Scholar] [CrossRef]
- Rodriguez-Rodriguez, R. Oleanolic acid and related triterpenoids from olives on vascular function: Molecular mechanisms and therapeutic perspectives. Curr. Med. Chem. 2015, 22, 1414–1425. [Google Scholar] [CrossRef]
- Wehner, A.; Hartmann, K.; Hirschberger, J. Associations between proteinuria, systemic hypertension and glomerular filtration rate in dogs with renal and non-renal diseases. Vet. Rec. 2008, 162, 141–147. [Google Scholar] [CrossRef]
- Lippi, I.; Perondi, F.; Ceccherini, G.; Marchetti, V.; Guidi, G. Effects of probiotic VSL#3 on glomerular filtration rate in dogs affected by chronic kidney disease: A pilot study. Can. Vet. J. Rev. Vet. Can. 2017, 58, 1301–1305. [Google Scholar]
- Summers, S.; Quimby, J. Insights into the gut-kidney axis and implications for chronic kidney disease management in cats and dogs. Vet. J. 2024, 306, 106181. [Google Scholar] [CrossRef]
- Nallu, A.; Sharma, S.; Ramezani, A.; Muralidharan, J.; Raj, D. Gut microbiome in chronic kidney disease: Challenges and opportunities. Transl. Res. J. Lab. Clin. Med. 2017, 179, 24–37. [Google Scholar] [CrossRef]
- Yoshifuji, A.; Wakino, S.; Irie, J.; Tajima, T.; Hasegawa, K.; Kanda, T.; Tokuyama, H.; Hayashi, K.; Itoh, H. Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc. 2016, 31, 401–412. [Google Scholar]
- Wang, X.H.; Mitch, W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014, 10, 504–516. [Google Scholar] [CrossRef] [PubMed]
- Brunetto, M.A.; Ruberti, B.; Halfen, D.P.; Caragelasco, D.S.; Vendramini, T.H.A.; Pedrinelli, V.; Macedo, H.T.; Jeremias, J.T.; Pontieri, C.F.F.; Ocampos, F.M.M.; et al. Healthy and Chronic Kidney Disease (CKD) Dogs Have Differences in Serum Metabolomics and Renal Diet May Have Slowed Disease Progression. Metabolites 2021, 11, 782. [Google Scholar] [CrossRef] [PubMed]
- Zatelli, A.; Pierantozzi, M.; D’Ippolito, P.; Bigliati, M.; Zini, E. Effect of dietary supplements in reducing probability of death for uremic crises in dogs affected by chronic kidney disease (masked RCCT). Sci. World J. 2012, 2012, 219082. [Google Scholar] [CrossRef]
- Brown, S.A. Oxidative Stress and Chronic Kidney Disease. Vet. Clin. N. Am. Small Anim. Pract. 2008, 38, 157–166. [Google Scholar] [CrossRef]
- Pasquini, A.; Guidi, G.; Marchetti, V.; Simoni, S.; Lubas, G.; Cardini, G. Use of D-Roms Assay in Dogs Affected by Chronic Renal Failure to Evaluate Prognosis: Preliminary Results. Abstr. Ecvim 2007, 17, 232. [Google Scholar]
- Silva, A.C.; de Almeida, B.F.; Soeiro, C.S.; Ferreira, W.L.; de Lima, V.M.; Ciarlini, P.C. Oxidative stress, superoxide production, and apoptosis of neutrophils in dogs with chronic kidney disease. Can. J. Vet. Res. Rev. Can. Rech. Vet. 2013, 77, 136–141. [Google Scholar]
- Halfen, D.P.; Caragelasco, D.S. Evaluation of Electrolyte Concentration and Pro-Inflammatory and Oxidative Status in Dogs with Advanced Chronic Kidney Disease under Dietary Treatment. Toxins 2019, 12, 3. [Google Scholar] [CrossRef]
- Chen, H.; Segev, G. Evaluation of oxidative stress in dogs and cats with chronic kidney disease. J. Vet. Intern. Med. 2024, 38, 3105–3110. [Google Scholar] [CrossRef]
- Irazabal, M.V.; Torres, V.E. Reactive Oxygen Species and Redox Signaling in Chronic Kidney Disease. Cells 2020, 9, 1342. [Google Scholar] [CrossRef]
- Brown, S.A.; Brown, C.A.; Crowell, W.A.; Barsanti, J.A.; Allen, T.; Cowell, C.; Finco, D.R. Beneficial effects of chronic administration of dietary omega-3 polyunsaturated fatty acids in dogs with renal insufficiency. J. Lab. Clin. Med. 1998, 131, 447–455. [Google Scholar] [CrossRef]
- Brown, S.A.; Finco, D.R.; Brown, C.A. Is there a role for dietary polyunsaturated fatty acid supplementation in canine renal disease? J. Nutr. 1998, 128, S2765–S2767. [Google Scholar] [CrossRef]
- Vastolo, A.; Iliano, S.; Laperuta, F.; Pennacchio, S.; Pompameo, M.; Cutrignelli, M.I. Hemp Seed Cake as a Novel Ingredient for Dog’s Diet.Front. Vet. Sci. 2021, 8, 754625. [Google Scholar] [CrossRef]
Ingredients | % |
---|---|
Feed supplement | |
Vitamin B12 1/1000 | 10 |
Vitamin E | 0.002 |
Vitamin B6 Chlorhydrate | 0.5 |
Vitamin C | 5 |
Folic acid | 0.2 |
Lactobacillus acidophilus D2/CSL | 0.211 |
Olea europaea L.: Olive extract | 2 |
Chitosan | 8 |
Sodium Bicarbonate | 6 |
Colloidal silica E551b | 0.5 |
Calcium carbonate | 26 |
Calcium lactate-gluconate | 16 |
Fructo-oligosaccharides (Profeed® Maxflow) | 20 |
Optimizor Uranus | 0.2 |
Maltodextrin | 5.387 |
Total | 100.000 |
Placebo | |
Maltodextrin | 95.00 |
Appetite stimulants | 5.00 |
Total | 100.000 |
TRT Group | CTR Group | ||
---|---|---|---|
Parameter | Time | Mean (Min–Max) | Mean (Min–Max) |
BW | 0 | 18.15 (7.1–29.8) | 14.46 (6.2–27.2) |
1 | 18.21 (7.1–29.9) | 14.44 (6.2–27.1) | |
2 | 18.31 (7.2–30.0) ** | 14.43 (6.1–27.0) | |
3 | 18.42 (7.5–30.1) ** | 14.42 (6.0–27.0) | |
BCS | 0 | 3.20 (2–4) | 2.73 (2–4) |
1 | 3.27 (2–4) | 2.73 (2–4) | |
2 | 3.40 (2–4) a | 2.73 (2–4) b | |
3 | 3.73 (3–5) A ** | 2.73 (2–4) B |
TRT Group | CTR Group | |||
---|---|---|---|---|
Parameter | Time | Range | Mean (Min–Max) | Mean (Min–Max) |
DBP | 0 | <95 | 84.67 (80–90) a | 80.67 (80–90) b |
1 | 87.33 (80–90) | 86.00 (80–90) ** | ||
2 | 84.00 (80–90) | 86.67 (80–90) ** | ||
3 | 84.00 (80–90) A | 90.00 (80–90) B ** | ||
SBP | 0 | <150 | 143.00 (130–150) | 142.00 (140–150) |
1 | 136.00 (120–150) B * | 150.00 (140–170) A ** | ||
2 | 136.33 (130–150) B * | 153.67 (140–180) A ** | ||
3 | 134.00 (120–150) B ** | 156.67 (140–170) A ** |
TRT Group | CTR Group | |||
---|---|---|---|---|
Parameter | Time | Range | Mean (Min–Max) | Mean (Min–Max) |
CREA | 0 | <1.4 mg/dL | 3.16 (2.70–3.60) | 3.24 (2.80–3.60) |
1 | 3.15 (2.60–3.80) | 3.31 (2.50–3.90) | ||
2 | 3.12 (2.50–3.60) | 3.27 (2.80–4.00) | ||
3 | 3.19 (2.70–3.80) | 3.25 (2.60–3.90) | ||
BUN | 0 | 15–45 mg/dL | 113.53 (82.80–150.80) b | 131.46 (103.00–163.00) a |
1 | 111.22 (85.30–147.20) B | 143.95 (119.00–182.60) A ** | ||
2 | 110.93 (85.00–148.10) B | 156.31 (124.10–189.70) A ** | ||
3 | 106.67 (82.20–143.30) B ** | 168.93 (133.30–198.30) A ** | ||
P | 0 | 3.5–4.7 mg/dL | 7.64 (6.00–8.80) | 8.11 (7.60–8.80) |
1 | 7.39 (5.60–8.70) B ** | 8.36 (7.60–9.10) A ** | ||
2 | 7.18 (5.60–8.40) B ** | 8.60 (7.80–9.50) A ** | ||
3 | 6.93 (5.30–8.30) B ** | 8.83 (7.90–9.80) A ** | ||
PT | 0 | 6–7.5 mg/dL | 5.59 (5.00–6.50) | 5.70 (5.00–6.50) |
1 | 5.85 (5.10–6.80) ** | 5.50 (4.90–6.20) ** | ||
2 | 6.01 (5.20–6.90) A ** | 5.33 (4.60–6.10) B ** | ||
3 | 6.11 (5.20–6.90) A ** | 5.19(4.40–5.90) B ** | ||
Alb | 0 | 2.5–4.2 mg/dL | 2.01 (1.50–2.50) | 1.97 (1.50–2.50) |
1 | 2.16 (1.60–2.70) a ** | 1.82 (1.20–2.50) b ** | ||
2 | 2.28 (1.60–2.80) A ** | 1.70 (1.00–2.30) B ** | ||
3 | 2.43 (1.70–2.90) A ** | 1.59 (0.70–2.30) B ** | ||
A/G | 0 | 0.8–1.3 mg/dL | 0.86 (0.70–1.00) b | 1.01 (0.50–1.30) a |
1 | 0.85 (0.60–1.10) b | 1.01 (0.60–1.30) a | ||
2 | 0.85 (0.70–1.10) | 0.93 (0.60–1.30) | ||
3 | 0.86 (0.60–1.10) | 0.87(0.50–1.30) | ||
SDMA | 0 | <14 µg/dL | 33.60 (29.00–38.00) | 34.40 (30.00–39.00) |
1 | 33.53 (28.00–41.00) | 35.60 (29.00–42.00) | ||
2 | 33.00 (27.00–38.00) | 35.07 (30.00–43.00) | ||
3 | 32.40 (29.00–38.00) B | 35.80 (29.00–42.00) A * |
TRT Group | CTR Group | |||
---|---|---|---|---|
Parameter | Time | Range | Mean (Min–Max) | Mean (Min–Max) |
PU | 0 | 0–150 mg/dL | 239.92 (233.50–266.70) | 235.73 (180.40–297.90) |
1 | 233.48 (194.20–264.80) ** | 243.59 (186.50–307.90) ** | ||
2 | 228.54 (190.20–263.30) b ** | 255.85 (196.50–313.70) a ** | ||
3 | 223.73 (185.80–255.90) B ** | 269.63 (205.00–332.50) A ** | ||
UPC | 0 | <0.5 | 0.66 (0.60–0.70) | 0.73 (0.60–0.90) |
1 | 0.55 (0.40–0.70) B ** | 0.81 (0.60–1.10) A | ||
2 | 0.44 (0.30–0.70) B ** | 0.88 (0.60–1.20) A ** | ||
3 | 0.35 (0.10–0.70) B ** | 0.96 (0.70–1.30) A ** | ||
USG | 0 | 1020–1040 | 1017 (1012–1020) a | 1014 (1011- 1018) b |
1 | 1019 (1012–1023) A ** | 1012 (1006–1018) B ** | ||
2 | 1022 (1016–1025) A ** | 1010 (1004–1017) B ** | ||
3 | 1024 (1021–1027) A ** | 1007 (999–1014) B ** |
TRT Group | CTR Group | |||
---|---|---|---|---|
Parameter | Time | Range | Mean (Min–Max) | Mean (Min–Max) |
CRP | 0 | 0–0.1 mg/dL | 0.53 (0.18–1.03) | 0.66 (0.04–1.06) |
1 | 0.50 (0.15–0.99) | 0.67 (0.04–1.07) | ||
2 | 0.47 (0.10–0.94) b * | 0.74 (0.04–1.21) a ** | ||
3 | 0.44 (0.05–0.90) B ** | 0.84 (0.24–1.31) A ** | ||
d-ROMs | 0 | - | 112.13 (100.60–125.30) | 114.85 (102.80–129.60) |
1 | 105.53 (94.40–121.30) B ** | 120.45 (110.80–136.60) A ** | ||
2 | 101.73 (89.90–118.30) B ** | 124.71 (115.30–136.60) A ** | ||
3 | 96.19 (80.40–111.90) B ** | 129.38 (118.30–141.60) A ** |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Perondi, F.; Ruggiero, A.; Cutrignelli, M.I.; Lippi, I.; Meineri, G.; Martello, E. Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease. Animals 2025, 15, 2884. https://doi.org/10.3390/ani15192884
Perondi F, Ruggiero A, Cutrignelli MI, Lippi I, Meineri G, Martello E. Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease. Animals. 2025; 15(19):2884. https://doi.org/10.3390/ani15192884
Chicago/Turabian StylePerondi, Francesca, Alessio Ruggiero, Monica Isabella Cutrignelli, Ilaria Lippi, Giorgia Meineri, and Elisa Martello. 2025. "Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease" Animals 15, no. 19: 2884. https://doi.org/10.3390/ani15192884
APA StylePerondi, F., Ruggiero, A., Cutrignelli, M. I., Lippi, I., Meineri, G., & Martello, E. (2025). Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease. Animals, 15(19), 2884. https://doi.org/10.3390/ani15192884